BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival
收藏NIAID Data Ecosystem2026-05-01 收录
官方服务：
资源简介：
We demonstrated that secondary Plasma Cell Leukemia, addicted to BCLXL, a small but a very challenging group of patients, could benefit from DT2216, underpinning its clinical evaluation. RNA CD138 positive human plasma cells were extracted with RNeasy Mini Kit (Qiagen) and sequenced on 3’ends.
创建时间：
2024-04-30
